Pioglitazone-induced body weight gain is prevented by combined administration with the lipoprotein lipase activator NO-1886

European Journal of Pharmacology

Volumn 668, Issue 3, 2011, Pages 486-491

  Kusunoki, Masataka ^a   Tsutsumi, Kazuhiko ^b   Sato, Daisuke ^c   Nakamura, Aki ^d   Habu, Satoshi ^a   Mori, Yuichi ^e   Morishita, Munehiko ^a   Yonemoto, Takayuki ^a   Miyata, Tetsuro ^f   Nakaya, Yutaka ^d   Nakamura, Takao ^c  

^a AICHI MEDICAL UNIVERSITY   (Japan)

^b Okinaka Memorial Institute for Medical Research   (Japan)

^c YAMAGATA UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKUSHIMA   (Japan)

^e Chukyo Women's University   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

Author keywords

Body weight gain; Insulin resistance; Lipoprotein lipase activator; Pioglitazone

Indexed keywords

ADIPONECTIN; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IBROLIPIM; INSULIN; LEPTIN; LIPID; LIPOPROTEIN LIPASE ACTIVATOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; RECOMBINANT HUMAN INSULIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; BODY WEIGHT DISORDER; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG POTENTIATION; FATTY ACID BLOOD LEVEL; FOOD INTAKE; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPID BLOOD LEVEL; LIPID DIET; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ABDOMINAL FAT; ADIPONECTIN; ANIMALS; BENZAMIDES; BLOOD GLUCOSE; BODY WEIGHT; DRUG COMBINATIONS; EATING; ENZYME ACTIVATION; HYPOGLYCEMIC AGENTS; INSULIN; LEPTIN; LIPIDS; LIPOPROTEIN LIPASE; MALE; ORGANOPHOSPHORUS COMPOUNDS; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLIDINEDIONES;

EID: 80053573926     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.07.030     Document Type: Article

References (26)

1. D.B. Allison, K.R. Fontaine, J.E. Manson, J. Stevens, and T.B. VanItallie Annual deaths attributable to obesity in the United States JAMA 282 1999 1530 1538 (Pubitemid 29504046)
2. S. Aronoff, S. Rosenblatt, S. Braithwaite, J.W. Egan, A.L. Mathisen, and R.L. Schneider Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes Diabetes Care 23 2000 1605 1611
3. G. Boden, and M. Zhang Recent findings concerning thiazolidinediones in the treatment of diabetes Expert Opin. Investig. Drugs 15 2006 243 250 (Pubitemid 43338145)
4. C.J. de Souza, M. Eckhardt, K. Gagen, M. Dong, W. Chen, D. Laurent, and B.F. Burkey Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance Diabetes 50 2001 1863 1871 (Pubitemid 33641608)
5. J.A. Dormandy, B. Charbonnel, D.J. Eckland, E. Erdmann, M. Massi-Benedetti, I.K. Moules, A.M. Skene, M.H. Tan, P.J. Lefèbvre, G.D. Murray, E. Standl, R.G. Wilcox, L. Wilhelmsem, J. Betteridge, K. Birkeland, A. Golay, R.J. Heine, L. Korányi, M. Laakso, M. Mokáň, A. Norkus, V. Pirags, T. Podar, A. Scheen, W. Scherbaum, G. Schernthaner, O. Schmitz, J. Škrha, U. Smith, and J. Tatoň Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial Lancet 366 2005 1279 1289 (Pubitemid 41416583)
6. D. Einhorn, M. Rendell, J. Rosenzweig, J.W. Egan, A.L. Mathisen, and R.L. Schneider Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study Clin. Ther. 22 2000 1395 1409 (Pubitemid 32056079)
7. Y. Endo, M. Suzuki, H. Yamada, S. Horita, M. Kunimi, O. Yamazaki, A. Shirai, M. Nakamura, M. Iso-O, Y. Li, M. Hara, K. Tsukamoto, N. Moriyama, A. Kudo, H. Kawakami, T. Yamauchi, N. Kubota, T. Kadowaki, H. Kume, Y. Enomoto, Y. Homma, G. Seki, and T. Fujita Thiazolidinediones enhance sodium-coupled bicarbonate absorption from renal proximal tubules via PPARγ-dependent nongenomic signaling Cell Metab. 13 2011 550 561
8. K.R. Fontaine, D.T. Redden, C. Wang, A.O. Westfall, and D.B. Allison Years of life lost due to obesity JAMA 289 2003 187 193 (Pubitemid 36068706)
9. S. Hallakou, L. Doaré, F. Foufelle, M. Kergoat, M. Guerre-Millo, M.F. Berthault, I. Dugail, J. Morin, J. Auwerx, and P. Ferré Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat Diabetes 46 1997 1393 1399 (Pubitemid 27369074)
10. T. Hara, D. Cameron-Smith, G.J. Cooney, M. Kusunoki, K. Tsutsumi, and L.H. Storlien The actions of a novel lipoprotein lipase activator, NO-1886, in hypertriglyceridemic fructose-fed rats Metabolism 47 1998 149 153 (Pubitemid 28084147)
11. K. Hermansen, and L.S. Mortensen Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus Drug Saf. 30 2007 1127 1142 (Pubitemid 350172854)
12. T. Kadowaki, and T. Yamauchi Adiponectin and adiponectin receptors Endocr. Rev. 26 2005 439 451 (Pubitemid 40686653)
13. S. Kano, and M. Doi NO-1886 (ibrolipim), a lipoprotein lipase-promoting agent, accelerates the expression of UCP3 messenger RNA and ameliorates obesity in ovariectomized rats Metabolism 55 2006 151 158 (Pubitemid 43098981)
14. R. Kawamori, T. Kadowaki, M. Onji, Y. Seino, and Y. Akanuma Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus: postmarketing surveillance study in Japan Diabetes Res. Clin. Pract. 76 2007 229 235 (Pubitemid 46400132)
15. E.W. Kraegen, D.E. James, S.P. Bennett, and D.J. Chisholm In vivo insulin sensitivity in the rat determined by euglycemic clamp Am. J. Physiol. 245 1983 E1 E7
16. M. Kusunoki, L.H. Storlien, J. MacDessi, N.D. Oakes, C. Kennedy, D.J. Chisholm, and E.W. Kraegen Muscle glucose uptake during and after exercise is normal in insulin-resistant rats Am. J. Physiol. 264 1993 E167 E172
17. M. Kusunoki, T. Hara, K. Tsutsumi, T. Nakamura, T. Miyata, F. Sakakibara, S. Sakamoto, H. Ogawa, Y. Nakaya, and L.H. Storlien The lipoprotein lipase activator, NO-1886, suppresses fat accumulation and insulin resistance in rats fed a high-fat diet Diabetologia 43 2000 875 880 (Pubitemid 30463167)
18. M. Kusunoki, K. Tsutsumi, T. Hara, H. Ogawa, T. Nakamura, T. Miyata, F. Sakakibara, Y. Fukuzawa, T. Suga, S. Kakumu, and Y. Nakaya A lipoprotein lipase activator, NO-1886 prevents impaired endothelium-dependent relaxation of aorta caused by exercise in aged rats Exp. Gerontol. 37 2002 891 896 (Pubitemid 34665479)
19. Y. Miyazaki, and R.A. DeFronzo Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients Diabetes Obes. Metab. 10 2008 1204 1211
20. O. Oz, E. Tuncel, S. Eryilmaz, M. Fazlioglu, C.B. Gul, C. Ersoy, N. Ocak, M. Dirican, S. Cangur, I. Baran, and S. Imamoglu Arterial elasticity and plasma levels of adiponectin and leptin in type 2 diabetic patients treated with thiazolidinediones Endocrine 33 2008 101 105
21. G. Schernthaner, D.R. Mattews, B. Charbonnel, M. Hanefeld, and P. Brunetti Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial J. Clin. Endocrinol. Metab. 89 2004 6068 6076 (Pubitemid 39628416)
22. B.M. Spiegelman PPAR-γ: adipogenic regulator and thiazolidinedione receptor Diabetes 47 1998 507 514 (Pubitemid 28160438)
23. L.H. Storlien, E.W. Kraegen, D.J. Chisholm, G.L. Ford, D.G. Bruce, and W.S. Pascoe Fish oil prevents insulin resistance induced by high-fat feeding in rats Science 237 1987 885 888 (Pubitemid 17128276)
24. K. Tsutsumi, Y. Inoue, A. Shima, K. Iwasaki, M. Kawamura, and T. Murase The novel compound NO-1886 increase lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis J. Clin. Invest. 92 1993 411 417 (Pubitemid 23209023)
25. K. Tsutsumi, Y. Inoue, A. Shima, and T. Murase Correction of hypertriglyceridemia with low high-density lipoprotein cholesterol by the novel compound NO-1886, a lipoprotein lipase-promoting agent, in STZ-induced diabetes rats Diabetes 44 1995 414 417
26. W. Yin, D. Liao, Z. Wang, S. Xi, K. Tsutsumi, T. Koike, J. Fan, G. Yi, Q. Zhang, Z. Yuan, and K. Tang NO-1886 inhibits size of adipocytes, suppresses plasma levels of tumor necrosis factor-α and free fatty acids, improves glucose metabolism in high-fat/high-sucrose-fed miniature pigs Pharmacol. Res. 49 2004 199 206 (Pubitemid 38064329)